There is a considerable concern regarding the inhibition of normal myelopoiesis during the development of novel CAR T cell therapies for myeloid malignancies based on the results of preclinical studies of scFv-based CAR T cells targeting CD33 or CD123 antigens [18–21]. The gene discussed is CD33; the disease is myeloid neoplasm.